12 results
Objectives: - to increase the proportion of patients with non-severe GVHD within 180 days post-allo-SCT - to reduce the progression rate - to improve the progression free survival- to asses the impact on the quality of life using a time restricted…
To evaluate the safety and tolerability of ascending single and multiple oral doses of ADX71441 as compared to placebo in healthy volunteers.To evaluate the pharmacokinetics of orally administered single and multiple doses of ADX71441 and its…
The objective is to determine whether ITB Therapy is more effective than oral anti-spasticity agents in reducing the spasticity.
To study the potential of baclofen as an anti-craving/relapse agent in GHB dependent patients.
Objectives: The primary aim of this study is to provide evidence for the effect of ITB treatment on the level of activities in dystonic CP patients.
The primary goal of the present study is to examine the efficacy of high dose baclofen for the treatment of patients with AD in a double-blind, randomized, placebo controlled study. Therefore high dose baclofen will be compared with placebo.…
The primary objective of this study in patients with symptomatic chronic Heart Failure and Preserved left ventricular Ejection Fraction (HF-PEF) is to determine whether ivabradine compared to placebo could improve the diastolic function, the…
The purpose of this study is to demonstrate the beneficial effect of ivabradine on endothelial function in individuals with risk factors for cardiovascular disease and a resting HR * 75 bpm.
The purpose of this study is to assess the safety of the new modified release (MR) formulation of ivabradine administered orally, at titrated doses if necessary, in patients with stable coronary artery disease (CAD) with or without angina pectoris.
Primary aim of the study is to compare the efficacy and safety of two flowrates of ITB while maintaining a constant daily dose.
The primary aim is to study the effect of treatment of severe AD patients with Myfortic on DNA-repair after irradiation with UVB.A secondary aim is to study the effect of treatment of severe AD patients on atopic status, measured as total IgE and…
To improve response rate of primary treatment of extensive chronic GvHD with the addition of MPA to the reference treatment CsA+PDN (comparator)Primary ObjectiveTo improve remission rates with cyclosporine A+ prednisone + Myfortic® (CsA+PDN+MPA)…